AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35321823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor in addition to aspirin
Number of subjects: 0
Study 35321823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35321823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 33333767 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive compounds enriched infant formula (EF)
Number of subjects: 70
Study 33333767 — intervention group
Group type: COMPARATOR
Intervention: Standard infant formula (SF)
Number of subjects: 70
Study 33333767 — intervention group
Group type: COMPARATOR
Intervention: Breastfed (BF)
Number of subjects: 70
Study 33333767 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal IQ
Number of subjects: 70
Study 33333767 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal educational level
Number of subjects: 70
Study 36206510 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle U-Dos technique (DB group)
Number of subjects: 72
Study 36206510 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle technique (SB group)
Number of subjects: 72
Study 34358486 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Bacillus coagulans MY01 and Bacillus subtilis MY02, 2·5 × 10^9 colony-forming units per capsule, consumed twice per day for 8 weeks)
Number of subjects: 68
Study 34358486 — intervention group
Group type: COMPARATOR
Intervention: Placebo (consumed twice per day for 8 weeks)
Number of subjects: 68
Study 34358486 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 68
Study 34358486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 32191532 — intervention group
Group type: EXPERIMENTAL
Intervention: EE 30 µg/DRSP 3 mg
Number of subjects: 60
Study 32191532 — intervention group
Group type: EXPERIMENTAL
Intervention: EE 30 µg/CMA 2 mg
Number of subjects: 60
Study 32191532 — intervention group
Group type: EXPERIMENTAL
Intervention: EE 30 µg/DNG 2 mg
Number of subjects: 60
Study 35513384 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led therapeutic carbohydrate and energy restriction
Number of subjects: 0
Study 33308285 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 10
Study 33308285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 34971039 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person family contact
Number of subjects: 146
Study 34971039 — intervention group
Group type: EXPERIMENTAL
Intervention: Text/email time with friends during COVID-19
Number of subjects: 146
Study 35953423 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patient (n=40)
Number of subjects: 81
Study 35953423 — intervention group
Group type: COMPARATOR
Intervention: Low-fidelity mannequin simulator (n=41)
Number of subjects: 81
Study 33541232 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch-and-go bench press
Number of subjects: 113
Study 33541232 — intervention group
Group type: COMPARATOR
Intervention: Concentric-only bench press
Number of subjects: 113
Study 33541232 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitions-to-failure test
Number of subjects: 113
Study 33541232 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with error in 1RM estimation
Number of subjects: 113
Study 32213105 — intervention group
Group type: EXPERIMENTAL
Intervention: Anetumab ravtansine at 6.5 mg/kg once every 3 weeks
Number of subjects: 148
Study 32213105 — intervention group
Group type: EXPERIMENTAL
Intervention: Anetumab ravtansine at 1.8 mg/kg once per week
Number of subjects: 148
Study 32213105 — intervention group
Group type: EXPERIMENTAL
Intervention: Anetumab ravtansine at 2.2 mg/kg once per week
Number of subjects: 148
Study 32213105 — intervention group
Group type: EXPERIMENTAL
Intervention: Anetumab ravtansine (various doses)
Number of subjects: 148
Study 35280163 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted digital sleep intervention
Number of subjects: 66
Study 35280163 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 66
Study 33266325 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein (HP) drinks
Number of subjects: 391
Study 33266325 — intervention group
Group type: COMPARATOR
Intervention: Normal Protein (NP) drinks
Number of subjects: 391
Study 33266325 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults
Number of subjects: 391
Study 33266325 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly
Number of subjects: 391
Study 33266325 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight categories, genders, and sites
Number of subjects: 391
Study 32787676 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 881
Study 32787676 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 881
Study 32787676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 881
Study 32603560 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation with aripiprazole
Number of subjects: 1522
Study 32603560 — intervention group
Group type: COMPARATOR
Intervention: Switching to bupropion
Number of subjects: 1522
Study 32603560 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation with bupropion
Number of subjects: 1522
Study 33147492 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adhesiolysis
Number of subjects: 184
Study 33147492 — intervention group
Group type: COMPARATOR
Intervention: Controlled ovarian stimulation and IUI
Number of subjects: 184
Study 35614437 — intervention group
Group type: EXPERIMENTAL
Intervention: Onset of physical disability
Number of subjects: 8568
Study 35614437 — intervention group
Group type: COMPARATOR
Intervention: No onset of physical disability or dementia
Number of subjects: 8568
Study 34913294 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg twice daily)
Number of subjects: 122
Study 34913294 — intervention group
Group type: COMPARATOR
Intervention: Ganirelix acetate (0.25 mg subcutaneously daily)
Number of subjects: 122
Study 32588878 — intervention group
Group type: EXPERIMENTAL
Intervention: Caplacizumab
Number of subjects: 100
Study 32588878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 36088351 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Replicating Effective Programs (REP)
Number of subjects: 0
Study 36088351 — intervention group
Group type: COMPARATOR
Intervention: Standard implementation
Number of subjects: 0
Study 33491323 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 oz of almonds daily for 12 weeks
Number of subjects: 39
Study 33491323 — intervention group
Group type: COMPARATOR
Intervention: 1.8 oz of pretzels daily for 12 weeks
Number of subjects: 39
Study 32605655 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment group
Number of subjects: 352
Study 32605655 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment group
Number of subjects: 352
Study 32605655 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment group
Number of subjects: 352
Study 32605655 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and postoperative orthodontic group
Number of subjects: 352
Study 32605655 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 352
Study 33065165 — intervention group
Group type: COMPARATOR
Intervention: TAVI with PSs
Number of subjects: 9498
Study 33065165 — intervention group
Group type: COMPARATOR
Intervention: TAVI with hdPSs
Number of subjects: 9498
Study 32187767 — intervention group
Group type: EXPERIMENTAL
Intervention: Take-home HIV test kit
Number of subjects: 0
Study 32187767 — intervention group
Group type: COMPARATOR
Intervention: Standard HIV testing methods
Number of subjects: 0
Study 35037386 — intervention group
Group type: COMPARATOR
Intervention: 1 ml minoxidil for external use twice a day
Number of subjects: 80
Study 35037386 — intervention group
Group type: EXPERIMENTAL
Intervention: 3500 IU basic fibroblast growth factor (bFGF) and 1 ml minoxidil for external use twice a day
Number of subjects: 80
Study 35037386 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 33161036 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedle (MN) patch
Number of subjects: 30
Study 33161036 — intervention group
Group type: COMPARATOR
Intervention: 30G hypodermic needle (positive control)
Number of subjects: 30
Study 33161036 — intervention group
Group type: COMPARATOR
Intervention: Microneedle patch with needles laying flat (negative control)
Number of subjects: 30
Study 32916656 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark Chocolate (DC)
Number of subjects: 12
Study 33385633 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medication
Number of subjects: 59
Study 32448277 — intervention group
Group type: EXPERIMENTAL
Intervention: TIDieR checklist
Number of subjects: 10
Study 32448277 — intervention group
Group type: EXPERIMENTAL
Intervention: CERT checklist
Number of subjects: 10
Study 32448277 — intervention group
Group type: EXPERIMENTAL
Intervention: CONTENT scale
Number of subjects: 10
Study 35676335 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patch (14 mg daily)
Number of subjects: 218
Study 35676335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 34182060 — intervention group
Group type: COMPARATOR
Intervention: Low abrasivity NaF and water control
Number of subjects: 96
Study 34182060 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium abrasivity NaF and SnF2
Number of subjects: 96
Study 36245011 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional Candida antigen every 3 weeks
Number of subjects: 50
Study 36245011 — intervention group
Group type: COMPARATOR
Intervention: Weekly DPCP application
Number of subjects: 50
Study 33407828 — intervention group
Group type: EXPERIMENTAL
Intervention: Hochu‐ekki‐to (HET) - 9 tablets, 2 times per day for 8 weeks
Number of subjects: 6000
Study 33407828 — intervention group
Group type: COMPARATOR
Intervention: Placebo - 9 tablets, 2 times per day for 8 weeks
Number of subjects: 6000
Study 33407828 — intervention group
Group type: EXPERIMENTAL
Intervention: HET
Number of subjects: 6000
Study 33407828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6000
Study 33155034 — intervention group
Group type: EXPERIMENTAL
Intervention: SaLeish vaccine (fusion protein of SP15 and LeIF)
Number of subjects: 0
Study 36179438 — intervention group
Group type: EXPERIMENTAL
Intervention: Online cognitive behavioral therapy (CBT) program
Number of subjects: 563
Study 36179438 — intervention group
Group type: COMPARATOR
Intervention: Access to anxiety resources on a static website (active comparator)
Number of subjects: 563
Study 36179438 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 563
Study 33788420 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 162
Study 33788420 — intervention group
Group type: COMPARATOR
Intervention: Non-statin users
Number of subjects: 162
Study 32124549 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (RT)
Number of subjects: 36
Study 32124549 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant radiotherapy (RT)
Number of subjects: 36
Study 33823560 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic-dose low molecular weight heparin (LMWH) - enoxaparin 1 mg/kg SQ/BID (CrCl ≥ 30 ml/min) or 0.5 mg/kg (CrCl 15-30 ml/min)
Number of subjects: 308
Study 33823560 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic/intermediate-dose LMWH or unfractionated heparin (UFH)
Number of subjects: 308
Study 33823560 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic-dose LMWH
Number of subjects: 308
Study 33823560 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 308
Study 33292892 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents as Teachers (PAT) intervention
Number of subjects: 132
Study 33292892 — intervention group
Group type: COMPARATOR
Intervention: Parents as Teachers (PAT) control
Number of subjects: 132
Study 34819126 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocovid capsules
Number of subjects: 202
Study 34819126 — intervention group
Group type: COMPARATOR
Intervention: Placebo containing palm superolein
Number of subjects: 202
Study 35361621 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) in elderly patients with T2D
Number of subjects: 2535
Study 35361621 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients with T2D with AF
Number of subjects: 2535
Study 34103326 — intervention group
Group type: EXPERIMENTAL
Intervention: Community and District-management Empowerment for Scale-up (CODES)
Number of subjects: 16
Study 34103326 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison areas)
Number of subjects: 16
Study 32407583 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF) intervention for 12 weeks
Number of subjects: 36
Study 32407583 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study 36272277 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended infusion of ampicillin/sulbactam (infused over 4 hours)
Number of subjects: 136
Study 36272277 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion of ampicillin/sulbactam (infused over 30 minutes)
Number of subjects: 136
Study 32965057 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Number of subjects: 0
Study 32965057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35396602 — intervention group
Group type: EXPERIMENTAL
Intervention: Domagrozumab (myostatin inhibitor)
Number of subjects: 120
Study 35396602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 35396602 — intervention group
Group type: EXPERIMENTAL
Intervention: Domagrozumab
Number of subjects: 120
Study 32729896 — intervention group
Group type: EXPERIMENTAL
Intervention: Target interlesion distance (ILD) of 5.0-6.0 mm
Number of subjects: 42
Study 32729896 — intervention group
Group type: EXPERIMENTAL
Intervention: Target interlesion distance (ILD) of 3.0-4.0 mm
Number of subjects: 42
Study 35793277 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardening
Number of subjects: 32
Study 35793277 — intervention group
Group type: EXPERIMENTAL
Intervention: Art-making
Number of subjects: 32
Study 32956528 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printed teeth models
Number of subjects: 90
Study 32217791 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron (PILL)
Number of subjects: 29
Study 32217791 — intervention group
Group type: COMPARATOR
Intervention: Transdermal iron (PATCH)
Number of subjects: 29
Study 34903440 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercises for 15 minutes preoperatively and on postoperative days 1, 2, and 3 after breathing exercise training.
Number of subjects: 63
Study 34903440 — intervention group
Group type: COMPARATOR
Intervention: Routine treatments and care process (Control group).
Number of subjects: 63
Study 34903440 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercises.
Number of subjects: 63
Study 32618725 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbial transplantation (FMT)
Number of subjects: 0
Study 35959574 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-intervention group (1-week after symptom onset)
Number of subjects: 31
Study 35959574 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-intervention group (2-week after symptom onset)
Number of subjects: 31
Study 35959574 — intervention group
Group type: COMPARATOR
Intervention: General treatment group
Number of subjects: 31
Study 35959574 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-intervention group
Number of subjects: 31
Study 33555337 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal repair
Number of subjects: 154
Study 33555337 — intervention group
Group type: COMPARATOR
Intervention: Postnatal repair
Number of subjects: 154
Study 34847737 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care consultation during hospital admission
Number of subjects: 365
Study 34847737 — intervention group
Group type: COMPARATOR
Intervention: Other inpatient wards (control)
Number of subjects: 365
Study 33098161 — intervention group
Group type: EXPERIMENTAL
Intervention: TFC-1067
Number of subjects: 48
Study 33098161 — intervention group
Group type: COMPARATOR
Intervention: 2% hydroquinone cream
Number of subjects: 48
Study 34969272 — intervention group
Group type: EXPERIMENTAL
Intervention: Line-to-line cementing
Number of subjects: 48
Study 34969272 — intervention group
Group type: COMPARATOR
Intervention: Standard cementing
Number of subjects: 48
Study 36124597 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic Regression (LR) model
Number of subjects: 9422
Study 36124597 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) model
Number of subjects: 9422
Study 34668872 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐CCM app on smartphones
Number of subjects: 6965
Study 34668872 — intervention group
Group type: COMPARATOR
Intervention: paper‐based CCM (control)
Number of subjects: 6965
Study 32316468 — intervention group
Group type: EXPERIMENTAL
Intervention: Methodology for detecting changes in travel behavior patterns using GPS/GNSS data and a clustering algorithm.
Number of subjects: 3
Study 35088103 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ng/kg/day calcitriol
Number of subjects: 68
Study 35088103 — intervention group
Group type: COMPARATOR
Intervention: 20 ng/kg/day calcitriol
Number of subjects: 68
Study 32843299 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (rTMS) for 2 sessions of 10 Hz rTMS (40 trains of 50 pulses with a 20-second intertrain interval) to the left dorsolateral prefrontal cortex
Number of subjects: 66
Study 32843299 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 66
Study 32385167 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.7 g of MSG
Number of subjects: 10
Study 32385167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 32289310 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic monitoring of bleeding risk using the HAS-BLED score via mAFA
Number of subjects: 1793
Study 32289310 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1793
Study 35950537 — intervention group
Group type: EXPERIMENTAL
Intervention: AHCC®
Number of subjects: 98
Study 35950537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 33619204 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive distal pancreatectomy (MIDP)
Number of subjects: 294
Study 33619204 — intervention group
Group type: COMPARATOR
Intervention: Open distal pancreatectomy
Number of subjects: 294
Study 32092081 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation protocol (2-6mA)
Number of subjects: 34
Study 35811053 — intervention group
Group type: EXPERIMENTAL
Intervention: aPDT with TBO and diode laser (635 nm)
Number of subjects: 71
Study 35811053 — intervention group
Group type: EXPERIMENTAL
Intervention: aPDT with ICG and diode laser (808 nm)
Number of subjects: 71
Study 35811053 — intervention group
Group type: COMPARATOR
Intervention: Conventional disinfection method with Phosphoric acid 37%
Number of subjects: 71
Study 33789445 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐alanine (n=11)
Number of subjects: 16
Study 33789445 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL, n=5)
Number of subjects: 16
Study 33789445 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive VL
Number of subjects: 16
Study 33789445 — intervention group
Group type: EXPERIMENTAL
Intervention: Type-I fibers in inactive VL
Number of subjects: 16
Study 32253597 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 51
Study 32253597 — intervention group
Group type: COMPARATOR
Intervention: Non-TXA
Number of subjects: 51
Study 34292116 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based U = U message
Number of subjects: 314
Study 34292116 — intervention group
Group type: EXPERIMENTAL
Intervention: Opinion-based message
Number of subjects: 314
Study 34292116 — intervention group
Group type: COMPARATOR
Intervention: Control message
Number of subjects: 314
Study 34393156 — intervention group
Group type: EXPERIMENTAL
Intervention: ZOL combined with APAP
Number of subjects: 109
Study 34393156 — intervention group
Group type: COMPARATOR
Intervention: ZOL without APAP (non-APAP group)
Number of subjects: 109
Study 34393156 — intervention group
Group type: EXPERIMENTAL
Intervention: ZOL combined with ELD
Number of subjects: 109
Study 34393156 — intervention group
Group type: COMPARATOR
Intervention: ZOL without ELD (non-ELD group)
Number of subjects: 109
Study 34963099 — intervention group
Group type: EXPERIMENTAL
Intervention: Human umbilical cord-derived mesenchymal stem cells (UC-MSC)
Number of subjects: 100
Study 32279430 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sacrohysteropexy (LSH)
Number of subjects: 0
Study 32279430 — intervention group
Group type: COMPARATOR
Intervention: Vaginal sacrospinous hysteropexy (SSHP)
Number of subjects: 0
Study 35820076 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidates with tattoos
Number of subjects: 183
Study 35820076 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidates with purple hair
Number of subjects: 183
Study 35820076 — intervention group
Group type: COMPARATOR
Intervention: Candidates with a Liverpool English accent
Number of subjects: 183
Study 34206175 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (body weight, elastic bands, water canes) twice per week for eight months
Number of subjects: 101
Study 34206175 — intervention group
Group type: COMPARATOR
Intervention: Control group (informed about national PA guidelines and received motivational talks)
Number of subjects: 101
Study 33051340 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Stereotactic Body Radiation Therapy (SBRT; 50 Gy in 4 fractions)
Number of subjects: 100
Study 33051340 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Traditional Radiation Therapy (45 Gy in 15 fractions)
Number of subjects: 100
Study 33051340 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab alone
Number of subjects: 100
Study 33051340 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + RT (regardless of schema)
Number of subjects: 100